Metastatic Colorectal Cancer
Conditions
Brief summary
The purpose of this study is to describe the treatments received and outcomes of patients with metastatic colorectal cancer, what percentage of these patients have K-Ras mutation of the tumor, and to describe the costs of treatments. Information will also be collected regarding risk factors, variables among treatment centers and patients, and explorative analyses will be done to try to identify factors that impact prognosis and factors that predict tolerability and response to treatment.
Interventions
None listed
Sponsors
National Cancer Institute, Naples
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologic diagnosis colorectal carcinoma * Metastatic disease * Signed informed consent
Exclusion criteria
* Prior treatment of metastatic colorectal cancer * Refusal or incapability of providing informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| percentage of patients enrolled in a clinical trial | two years |
| percentage of patients who undergo K-Ras mutation study | 2 years |
| Percentage of patients with K-Ras mutation | 2 years |
Other
| Measure | Time frame | Description |
|---|---|---|
| disease outcome per patient per treatment received | 2 years | — |
| metastatic colorectal cancer treatments used in clinical practice, according to participating center | 2 years | — |
| predictive factors for response to treatment | 5 years | exploratory analyses |
| factors that influence patient prognosis | 2 years | exploratory analyses |
| patient outcome according to K-Ras status | two years | — |
| estimated costs per treatment per center | 2 years | — |
Countries
Italy
Outcome results
None listed